Evidence map›Paper›PMID 41965828›Full record

ReviewCommunications medicine2026

Advancing regenerative medicine with RNA nanotechnology for chronic and end organ diseases.

Anita Bakrania, Anh-Thu Nguyen Lefebvre, Rienk de Vries, Michael A Laflamme, Elmar Jaeckel, Housheng Hansen He, Laszlo Radvanyi, Sarah Hedtrich, Gaurav Sahay, Anna Blakney and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anita BakraniaToronto General Hospital Research Institute, Toronto, ON, Canada.
Anh-Thu Nguyen LefebvreAjmera Transplant Program, University Health Network, Toronto, ON, Canada.
Rienk de VriesCanadian Donation and Transplantation Research Program, Toronto, ON, Canada.
Michael A LaflammeMcEwen Stem Cell Institute, University Health Network, Toronto, ON, Canada.
Elmar JaeckelAjmera Transplant Program, University Health Network, Toronto, ON, Canada.
Housheng Hansen HePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Laszlo RadvanyiOntario Institute for Cancer Research, Toronto, ON, Canada.
Sarah HedtrichFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-6770-3657
Gaurav SahayDepartment of Pharmaceutical Sciences, College of Pharmacy, Robertson Life Sciences Building, Oregon State University, Portland, OR, USA.
Anna BlakneyMichael Smith Laboratories, School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0002-5812-9689
Michael SeftonDepartment of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada.
Bowen LiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Gang ZhengPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-0705-7398
Mamatha BhatToronto General Hospital Research Institute, Toronto, ON, Canada. Mamatha.Bhat@uhn.ca.ORCID http://orcid.org/0000-0003-1960-8449

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapies for chronic and end-organ diseases are often associated with systemic toxicity, and such conditions result in difficulty treating patients. RNA nanomedicine has demonstrated unprecedented advantages in the field of therapeutics through its selective organ targeting, personalized treatment option and safety. In this paper, we extensively discuss the current state of nanotechnology in regenerative medicine and how this unique combination of RNA nanomedicine and regenerative medicine can be leveraged for a successful end-organ and chronic disease therapy. More specifically, we have put forward strategies to specifically deliver RNA nanomedicine to target organs/tissues in chronic disease patients, design considerations for regenerative medicine RNA therapy versus RNA vaccines, and barriers to clinical translation. We further discuss the call to action short- and long-term goals in the field of regenerative RNA nanomedicine that could change the face of regenerative medicine in the coming years.

Identifiers

PMID41965828
PMCPMC13070041

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.